Sjögren's disease & overlap diseases
Anti-survival motor neuron complex antibodies as a novel biomarker for pulmonary arterial hypertension and interstitial lung disease in mixed connective tissue disease
Authors' conclusion
Anti-SMN complex Abs is the first biomarker of a typical subset of MCTD which bears organ damages such as PAH and ILD.
Study context
- Population
- Newly diagnosed consecutive cases of SLE, SSc or MCTD with anti-U1 RNP antibodies (Abs), April 2014–August 2022
- Participants
- 158 participants
- Exposure
- Anti-SMN complex Abs-positive vs negative patients; prevalence across MCTD, SLE and SSc
- Outcome
- Prevalence of anti-SMN complex Abs (immunoprecipitation) and association with clinical characteristics
Methodological detailsconsecutive newly diagnosed cases
- Consecutive newly diagnosed cases
Main finding
As reported in the abstract
Anti-SMN complex Abs prevalence
Observational data: associations, not effects.
Further findings
Anti-SMN complex Abs in MCTD subsets
- Highest prevalence in subset with clinical features of all three components (SLE, SSc, IIM)
PAH and interstitial lung disease (ILD) in MCTD by anti-SMN complex Abs status
- Anti-SMN complex Abs-positive MCTD had higher prevalence of PAH and ILD than negative patients
Death within 1 year of treatment
- All three deaths were positive for anti-SMN complex Abs
- 3
Original publication
Anti-survival motor neuron complex antibodies as a novel biomarker for pulmonary arterial hypertension and interstitial lung disease in mixed connective tissue disease. Rheumatology (Oxford). Published 8 July 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →